Valuation: Sprint Bioscience AB

Market Cap 29Cr 2.96Cr 2.96Cr 2.57Cr 2.42Cr 2.2Cr 4.12Cr 283.74Cr 4.15Cr 11Cr 143.94Cr 11Cr 11Cr 457.62Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 29Cr 2.96Cr 2.96Cr 2.57Cr 2.42Cr 2.2Cr 4.12Cr 283.74Cr 4.15Cr 11Cr 143.94Cr 11Cr 11Cr 457.62Cr EV / Sales 2026 *
3.33x
EV / Sales 2027 * 2.99x
Free-Float
72.16%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 42 01/10/2023
Chief Tech/Sci/R&D Officer 55 01/01/2009
Director of Finance/CFO 55 04/05/2026
Director TitleAgeSince
Chairman 70 01/01/2010
Director/Board Member 50 01/01/2019
Chairman 58 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
+5.04%+3.66%+50.62%+103.77% 7.02TCr
-0.67%-0.39%+35.17%+75.89% 6.26TCr
-3.18%-0.78%-14.14%+369.82% 2.74TCr
-0.16%-0.49%+26.31%+11.75% 2.57TCr
+2.20%-4.72%+2.19%-13.14% 2.48TCr
-0.64%-2.49%+18.66%-20.88% 1.95TCr
-7.03%-10.19%+161.91%+303.00% 1.55TCr
-4.45%-5.78%-9.67%+482.03% 1.47TCr
+4.96%+4.63%-2.75%+864.40% 1.47TCr
Average -0.43%-1.83%+29.81%+241.85% 3.06TCr
Weighted average by Cap. +0.60%-0.80%+31.97%+167.90%

Financials

2026 *2027 *
Net sales 8.68Cr 88.88L 88.88L 77.01L 72.68L 65.93L 1.24Cr 85Cr 1.25Cr 3.34Cr 43Cr 3.34Cr 3.26Cr 137.39Cr 9.68Cr 99.12L 99.12L 85.89L 81.05L 73.53L 1.38Cr 95Cr 1.39Cr 3.73Cr 48Cr 3.72Cr 3.64Cr 153.22Cr
Net income - -
Net Debt - -
Logo Sprint Bioscience AB
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!